University of South Carolina

Scholar Commons
Theses and Dissertations
2016

Morphogenic Effects Of Dopamine In Cultured Rat Hippocampal
Astrocytes
Ashley L. Galloway
University of South Carolina

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Biomedical and Dental Materials Commons

Recommended Citation
Galloway, A. L.(2016). Morphogenic Effects Of Dopamine In Cultured Rat Hippocampal Astrocytes.
(Master's thesis). Retrieved from https://scholarcommons.sc.edu/etd/3855

This Open Access Thesis is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and
Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
digres@mailbox.sc.edu.

MORPHOGENIC EFFECTS OF DOPAMINE IN CULTURED RAT HIPPOCAMPAL
ASTROCYTES
by
Ashley L. Galloway
Bachelor of Science
University of Tennessee at Chattanooga, 2014

Submitted in Partial Fulfillment of the Requirements
For the Degree of Master of Science in
Biomedical Sciences
School of Medicine
University of South Carolina
2016
Accepted by:
Pavel I. Ortinski, Director of Thesis
Jill R. Turner, Reader
David D. Mott, Reader
Paul Allen Miller, Vice Provost and Interim Dean of Graduate Studies

© Copyright by Ashley L. Galloway, 2016
All Rights Reserved

ii

ACKNOWLEDGEMENTS

I would like to thank everyone from the PPN department that I have known
during my time here. Every single one has contributed in some way to this thesis.
Foremost I would like to thank my primary instructor/supervisor, Dr. Pavel
Ortinski, for his patience and encouragement throughout this project; for
providing me with limitless opportunity and for opening up the world of
neuro(science) to me. To my committee, Dr. Pavel Ortinski, Dr. Jill Turner, and
Dr. David Mott, I am extremely grateful for your mentorship and guidance
throughout my time as a Masters student and throughout my project.
To my significant other, Boone, thank you for keeping me sane, keeping
me fed, and keeping me happy. Finally, my family have always supported me
and it is to them that my greatest thanks must go, for getting me here and getting
me through.

iii

ABSTRACT

Dopamine is critical for processing of reward and addictive behaviors
brought about by drugs of abuse. Scientific investigation of drugs of abuse and
their effects on CNS function has traditionally been directed at understanding the
role of neurons. However, astrocytes, which constitute approximately half of all
human brain cells, play a dynamic role in many essential nervous system
functions, including neurotransmission, ion homeostasis, and immune defense.
Dopamine effects on astrocytes have been historically understudied, yet
research indicates that astrocytes express dopamine receptors and are sensitive
to dopaminergic activity. Importantly, astrocytes, comprise a morphologically
heterogeneous population of cells, and a distinction between polygonal
protoplasmic and stellated fibrous astrocytes in various CNS regions has long
been acknowledged. However, the molecular and functional implications of this
heterogeneity are largely unknown. Using an in vitro model of elevated
extracellular dopamine exposure, our evidence reveals a fast and dramatic
dopamine-induced switch from a protoplasmic to a fibrous-like morphology in
cultures of rat hippocampal astrocytes. A one hour exposure to dopamine (75µM)
produced an average of 4.5 more processes per astrocyte accompanied by a
significant decrease in GFAP-positive area. Treatment with dopamine receptor
antagonists prior to dopamine exposure significantly blunted
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dopamine effects on astrocyte morphology. Importantly, brief one hour treatment
with dopamine was found to upregulate mRNA for ST8SiaI (a marker of
fibrous/type 2 astrocytes), and downregulate mRNA for Ran2 (a marker of
protoplasmic cells/type 1 astrocytes). Quantitative RT-PCR analysis revealed a
dopamine-induced upregulation of DRD1, DRD2, and DRD3 mRNA. Together
these findings support the hypothesis that excess extracellular dopamine,
through action on an astrocyte-bound dopamine receptor, induces alterations in
astrocytic morphology and molecular profile. Functional implications of such
changes in drug abuse, a condition associated with elevated dopamine signaling,
remain to be examined
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CHAPTER 1
INTRODUCTION

First noted in 1824 and first named in 1856, glia have long been
acknowledged in neuroscientific literature (Virchow, 1856). Rudolf Virchow was
the first to apply a name to these cells, designating them as neuroglia or “nerveglue” (Virchow, 1856). For many years, neuroglia were regarded as inert cells
charged with providing structural support in order for neurons to function. Yet,
neuroglia or glia are now understood to play a multitude of diverse and crucial
roles in the brain ranging from immune responses to regulation of neural
networks. Neuroglia comprise an expansive population of brain cells (80 - 90%),
and can be grouped based on developmental origin, morphology, and function
into two main classes: microglia and macroglia (Ramon y Cajal S., 1913; Kandel
et al., 2012; Oberheim et al., 2012). Cells classified as macroglia include
astrocytes, oligodendrocytes, and oligodendrocyte precursor cells. Astrocytes
and oligodendrocytes have discrete functional responsibilities. While
oligodendrocytes ensheath CNS axons in myelin to promote rapid saltatory
conduction, astrocytes are understood to play particularly diverse roles within the
brain (Haydon et al., 2009; Oberheim et al., 2012; Araque et al., 2014).

1

Astrocytes are actively involved in metabolic homeostasis, ionic and pH
homeostasis, trophic support of neurons, antioxidant defense, and in the
establishment and maintenance of the blood brain barrier (Clarke and Barres,
2013; Fattore et al., 2002; Clark et al., 2013; Zamanian et al., 2012; Freeman
2010; Bushong 2004; Perea et al., 2009). Of particular note is the role of
astrocytes in formation, maturation, function, and survival of synapses,
particularly at developmentally relevant stages (Clarke and Barres, 2013). For
example, one well known molecular mechanism of early astro-genesis, the
JAK/STAT pathway, specifies astrocyte and neuronal proliferation and
differentiation, and plays a part in regulating synaptic plasticity (Nicolas et al.,
2013; Lee at al., 2016; Sloan and Barres, 2014). Importantly, astrocytes are often
first responders to system insult and have been found to produce a range of
inflammatory responses, including upregulated cytokine production, hypertrophy,
as well as, molecular and functional changes (Sofroniew, 2009; Zamanian et al.,
2012; Clark et al., 2013). Astrocytes are responsible for regulating the brain’s
neuronal environment which, in turn, supports proper cell signaling and provides
means for involvement in the processing of information (Halassa et al. 2007;
Fellin et al., 2004; D’Ascenzo et al., 2007; Narita et al., 2006). In fact, astrocytes
are often in close association with synaptic structures and express functional
receptors, meaning these cells are dynamically involved in synaptic transmission
and plasticity (Fattore et al., 2002; Clark et al., 2013; Freeman 2010; Bushong
2004; Perea et al., 2009). Finally, astrocytes are strongly implicated in the
pathogenesis of neurological diseases including Alzheimer’s, Parkinson’s,
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epilepsy, mood disorders, and drug addiction (Fattore et al., 2002; Vaarmann et
al., 2010; Schitine et al., 2015; Ortinski et al., 2010; Turner et al., 2013; Haydon
et al., 2009).

1.1

Astrocyte morphology
Neonatal culture preparations are a convenient, albeit simplified, model

used to examine astrocytic responses to environmental stimuli and to understand
the mechanisms that may guide such responses. Two distinct astrocytic
phenotypes have been identified in neonatal cultures: A2B5(-) protoplasmic and
A2B5(+) fibrous (Raff et al., 1983). Protoplasmic or type I astrocytes have many
fine processes and populate the grey matter while fibrous or type II astrocytes
present a clear stellate structure with long defined processes and are arranged
along white matter tracts (Raff et al., 1983; Oberheim et al., 2012). These
morphological and molecular distinctions may indicate differences in functional
responses and abilities including potassium buffering, calcium signaling, and
clearance of neurotransmitters from the extracellular space (Raff et al., 1983;
Montgomery, 1994; Zhang and Barres, 2010; Oberheim et al, 2012; Bushong et
al, 2004).
Found throughout the CNS, astrocytes are extremely heterogeneous in
their morphology, and likely serve diverse functions based on developmental,
morphological, and regional distinctions (Raff et al., 1983; Miller & Raff, 1984).
This thesis addresses two populations of astrocytic cell types identified in culture:
type 1 and type 2 astrocytes. Type 1 astrocytes are thought to represent
protoplasmic astrocytes found in the gray matter due to their finely branched
3

processes and overall bushy appearance. Viewed under a light microscope (i.e.,
brightfield, DIC), type 1 astrocyte processes form a polygonal or cloud-like
morphology due to highly ramified fine processes (Bushong et al., 2002;
Bushong et al., 2004; Raff et al., 1983). Type 2 astrocytes are thought to closely
model fibrous astrocytes that populate white matter regions of the brain. Using a
light microscope, some defined processes of type 2 astrocytes can be seen;
however, GFAP staining in type 2 astrocytes depicts a definitively stellated (5 to
15 thick primary processes; Raff et al., 1983).
A distinction between astrocytes morphology in vitro and in vivo has been
recognized for many years. Astrocytes cultured in serum-containing media have
a flat polygonal appearance, while astrocytes in vivo possess a classical star-like
morphology with extending filopodia and lamellipodia (Raff et al., 1983; Miller &
Raff, 1984; Lavialle et al., 2011). Interestingly, cultured astrocytes can be
transformed to resemble their in vivo morphology by exposure to cAMP analogs,
serum-free media, and isoproterenol (Won and Oh, 2000; Raff et al., 1983; Miller
and Raff, 1984; Moonen, 1975; Ramsell et al., 1997; Shao and McCarthy, 1993).
This transformation is associated with decreased cell body area and production
and/or extension of distinct thick processes (Moonen, 1975; Ramsell et al., 1997;
Shao and McCarthy, 1993; Won and Oh, 2000). Notably, cAMP-induced
astrocyte stellation is region-specific: in contrast to cerebellar, cortical, and
hippocampal astrocytes, hypothalamic cells produce only mild stellation (Won
and Oh, 2000). Glutamate can block region-specific cAMP-induced stellation with
hippocampal and cerebral astrocytes being most effectively blocked (Won and
4

Oh, 2000). Taken together, these findings suggest that astrocytes derived from
different regions of the neonatal rat brain possess different degrees of
morphological plasticity in culture.

1.2

Dopaminergic activity in the hippocampus
In this thesis I use astrocytic cultures from the rat hippocampus. Within the

hippocampus, significant attention has been directed toward the
neuromodulatory effects of acetylcholine and noradrenaline with actions of
dopamine receiving less consideration (Hasselmo and Wyble, 1997; Murchison
et al., 2004). However, dopamine has been shown to regulate neuronal plasticity
in the hippocampus (Jay, 2003; Edelmann and Lessmann, 2013; Jenson et al.,
2015) and a subpopulation of dendritic spines in hippocampal pyramidal neurons
are simultaneously contacted by both dopaminergic and glutamatergic inputs
(Goldman-Rakic et at., 1989; Carr et al., 1999).
Studies investigating drug-induced synaptic plasticity found that repeated
cocaine exposure and withdrawal potentiates ventral hippocampal inputs in the
NAc shell (Barr et al., 2014). Other studies have found that cocaine elicits
enhancement of long term potentiation in the CA1 region of the hippocampus
(Thompson et al., 2005; Stramiello and Wagner, 2010; Keralpurath et al., 2014).
Further, repeated or prolonged cocaine exposure results in a number of
hippocampal-linked deficits in learning and memory (Briand et al., 2008).
Importantly, investigators have shown dopaminergic signaling in the
hippocampus is activated by novel stimuli (Li et al., 2003; Lisman & Grace,
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2005). A hippocampal-VTA loop has been speculated to function as a novelty
detector that regulates processing of behaviorally relevant signals in the
hippocampal formation in a dopamine-dependent manner (Lisman and Grace,
2005).

1.3

Astrocyte plasticity
Emerging evidence suggests a critical role of astrocytes in the integration

and processing of synaptic information within many regions of the brain. In
particular, astrocytes modulate neuronal activity, synaptic transmission, and
behavior through uptake and/or release of certain chemical transmitters, such as
glutamate, ATP, and d-serine in a process called gliotransmission (Haydon 2009,
Araque 2014, Koizumi 2003, Fellin 2004, Fellin 2007, Panatier 2006). These
transmitters provide important mechanisms by which neuronal functioning can be
regulated. For example, astrocytic release of ATP facilitates inhibition of
excitatory synaptic transmission in hippocampal cell populations as evidenced by
in vitro and ex vivo studies (Koizumi 2003, Kang 1998). Astrocytes have also
been recognized to remove transmitters, including glutamate, from the synaptic
cleft. Defined by its functional architecture, and termed the ‘tripartite synapse’,
the relationship between astrocytes and excitatory pre- and postsynaptic
neuronal synapses provides a strong argument for the regulation of synaptic
transmission by astroglial interactions (Covelo & Araque 2015, Haydon 2009).
Astroglia cells in vivo are able to retract or extend their processes in a
plastic manner to make contacts with local synapses, other astrocytic processes,
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or blood vessels (Oliet et al., 2001; Oberheim et al., 2012). Actin-type filaments
known as lamellipodia and filopodia composing the astroglial processes exert a
significant influence on synaptic architecture and physiology (Lavialle et al.,
2011; Park et al., 2015; Araque et al., 2014). Neurotransmitter release by
surrounding neurons may exert reciprocal regulatory action on astrocytes leading
to spatial extension and plasticity of astrocytic processes. For example, oxytocin
released during lactation can lead to changes in astrocyte morphology which
can, in turn, blunt release of neurotransmitters (Oliet et al., 2001). In Parkinson’s
Disease plastic changes in astrocyte morphology, such as upregulation of
primary process numbers, increases in individual process thickness, and
extension of processes have been observed to lead to an upregulation of
astroglial process-to-synapse wrapping and blanketing (Maragakis & Rothstein,
2006). In another study modeling Parkinson’s Disease, interruption of
dopaminergic transmission via lesioning resulted in a global increase in the
astrocytic calcium dynamics (frequency, amplitude, and duration), as well as an
increase in signaling synchrony and gap junction coupling within the substantia
nigra reticulata (SNr) network (Bosson et al., 2015).
Neuro-glial signaling at the tripartite synapse is reciprocal and supports
the concept of astrocytes acting as integral functional components of the
synapses they are locally associated with. Such association allows for inputspecific regulation of synaptic transmission and plasticity by astrocytes that may
serve as a feedback mechanism (Covelo and Araque, 2015) referred to as lateral
astrocyte synaptic regulation (Rouach et al., 2008; Covelo & Araque 2015).
7

Glutamate signaling may represent a metabolic correlate of lateral astrocyte
control of synaptic transmission (Covelo and Araque, 2015; Rouach et al., 2008;
Fellin 2004). Specifically, astrocytes have been credited for their role in recycling
glutamate, which exerts an important influence on excitatory and inhibitory
synaptic transmission in regions such as the hippocampus, prefrontal cortex, and
nucleus accumbens (Fellin et al., 2004; Fellin et al., 2007; Haydon et al., 2009;
Araque 2014; Kang 1998). This process may involve other neurotransmitter
pathways. For example, endocannabinoids released from pyramidal neurons in
the hippocampus can activate astrocyte-bound CB1 receptors leading to a PLCdependent elevation of astrocytic calcium levels (Navarette and Araque, 2010).
This mobilization of calcium stores stimulates release of astroglial glutamate
which activates NMDA receptors in pyramidal neurons (Navarette and Araque,
2010). In line with this, work on hippocampal neuronal and astrocytic cultures
also reported that calcium uncaging in astrocytes or mechanical and/or electrical
stimulation trigger glutamate gliotransmission that evokes slow inward excitatory
currents in adjacent neurons (Fellin et al., 2004, Haydon et al., 2009, Navarette
and Araque 2010, Perea and Araque, 2005). Furthermore, the threshold for
inducing NMDAR-dependent long-term potentiation (LTP) within the
hippocampus is lowered when astrocytic glutamate release accompanies LTP
induction, suggesting that astrocytic glutamate can modulate synaptic plasticity
(Park et al., 2015).
Synaptic regulation by astrocytes is not necessarily confined to local
active synapse(s). Considering the morphological and functional characteristics
8

of astrocytes, such as long-range propagation of the astrocyte calcium signal
(Perea and Araque, 2005; Di Castro et al., 2011; Panatier et al., 2011), the
intercellular coupling via gap-junctions, and the widespread branching of
processes that permit a single astrocyte to make contact with a multitude of
synapses (Bushong et al., 2002; Halassa et al., 2007; Lavialle et al., 2011), more
spatially extensive regulatory processes can be conceived. A recent observation
was made showing that genetic suppression of astrocytic IP3-dependent calcium
signaling diminishes astrocytic coverage of hippocampal synapses (Tanaka et
al., 2013). Importantly, the frequency of synaptic activity determines the
capability of Ca2+ signals to exert feedback regulatory mechanisms at local
active synapses or apply feedforward mechanisms at distant synapses (Haydon
et al., 2009; Volterra et al., 2014; Araque et al., 2014; Perea et al., 2014). Thus,
under some circumstances, gliotransmission can act in a highly localized fashion,
while other conditions may allow them to act at more distant sites (Araque et al.,
2014; Perea et al., 2014).
Studies of calcium dynamics have revealed autonomous functional
domains in astrocytes. That is, astrocytes’ calcium responses have traditionally
been observed in the cell soma; yet, recent evidence shows that calcium
responses can be generated in astrocytic processes that do not propagate to the
soma. Such functionally discrete domains allow for divergent functional
consequences. Depending on the morphology of discrete functional domains, a
single astrocyte could exert different effects on modulation of associated local or
distant synapses (Covelo and Araque, 2015; Volterra et al., 2014).
9

1.4

Astrocytes in addiction: morphology and function

Chronic exposure to drugs of abuse, including cocaine, has been shown to lead
to reactive astrocytosis (Bowers and Kalivas, 2003; Fattore et al., 2002).
Activated astrocytes are characterized by changes in morphology including cell
hypertrophy, increases in individual process thickness, and extension of
processes that is often associated with an expansion of astrocytic coverage of
synapses (Bowers and Kalivas, 2003; Fattore et al., 2002; Maragakis &
Rothstein, 2006; Narita et al., 2006). For example, following 1 and 7 days of
repeated cocaine administration, astrocytes in the mouse dentate gyrus
presented marked reactivity including process thickening and cell body
hypertrophy (Fattore et al., 2002). Such changes in astrocyte morphology
following exposure to drugs of abuse are likely accompanied by changes in
astrocytic function. For example, exposure to cocaine can lead to a reduction in
extracellular glutamate levels due to impaired activity of astrocytic
cysteine/glutamate transporters (Baker et al., 2003; Uys and Reissner, 2011).
Interestingly, astrocytic excitatory amino acid transporters (EAATs) have been
suggested as potential therapeutic targets for methamphetamine and cocaine
neurotoxicity (Lau et al., 2010). Considering the critical role of glutamate in
learning and drug-related behaviors associated with addiction (Kalivas, 2009;
Kalivas and Volkow, 2011, Turner et al., 2013), neurophysiological
consequences of drugs of abuse on astrocytes represent an important research
venue. Identification and characterization of structural changes that astrocytes
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undergo in response to drugs of abuse are a critical step in understanding such
consequences.

1.5

Dopaminergic physiology
Despite the findings implicating astrocytic signaling in addiction-related

processes, little is known about the effects of dopamine on astrocytes. Dopamine
serves as a critical neurotransmitter of the CNS and PNS systems, playing
important roles in regulating movement, as well as motivated behavior and
processing of reward. Ever since its original discovery, the dopaminergic system
and its’ intricate signaling networks have and continue to be a topic of exhaustive
scientific and clinical investigation. Dopamine is strongly implicated in
neuropathology of schizophrenia, Parkinson’s Disease, and addiction (Iversen et
al., 2009). Dopaminergic neurons populate two neighboring subregions of the
ventral mesencephalon: the Substantia Nigra (SN) and Ventral Tegmental Area
(VTA; Hokfelt et al., 1984). Three target areas, the striatum, the limbic system,
and the frontal cortices, receive efferent projections from one of the two above
mentioned midbrain regions (Hokfelt et al., 1984; Kandel et al., 2012). Each
pathway formed by these projections subserves a different set of functions and is
consequently implicated in distinct neuropathologies. Dopaminergic fibers
stemming from the more lateral region of the subtanta nigra pars reticulata (SNr)
help comprise the nigro-striatal system, a system involved in production/initiation
of movement, by forming functionally distinct parallel-processing loop(s) with the
basal ganglia (Iversen et al., 2009). Deficits in this system lead to significant
deficits in motor control (i.e., tremors, rigidity, postural imbalance) a pathological
11

marker of Parkinson’s disease (Kandel et al., 2012). The mesocortical pathway
originates in the VTA and terminates in the prefrontal cortex (PFC), and is
involved in higher cognitive processes such as working memory and goaldirected behaviors (Zahrt et al., 1997). The mesolimbic system sends projections
from the VTA to the Nucleus Accumbens (NAc) of the limbic system. Pathological
disturbance of this pathway has been implicated in schizophrenia, obsessivecompulsive disorder, and drug addiction. A pathway directed from the PFC to the
VTA and limbic system provides a circuit encompassing both the mesocortical
and mesolimbic projections. The mesolimbic pathway has been acknowledged
as a regulator of sensitized incentive salience or ‘wanting’ through action in the
amygdala, as well as, memory consolidation in the hippocampus (Robinson and
Berridge, 2008; Li et al., 2003; Da Silva et al., 2012). Addictive substances
upregulate dopaminergic activity within this complex reward system, resulting in
pathologically high reward values being assigned to cues that co-occur with drug
activity (Iversen et al., 2009; Kandel et al, 2012).
Dopamine exerts its physiological consequences predominantly through
stimulation of D1- like (DRD1, DRD5) or D2-like (DRD2, DRD3, DRD4)
metabotropic G-protein coupled receptors. Dopamine receptors span the plasma
membrane 7 times and have a cytoplasmic domain that binds to and interacts
with Gα and Gβγ proteins, as well as an extracellular domain that exclusively
binds dopamine (Iversen et al., 2009; Kandel et al., 2012). Ligand binding to D1like receptors stimulates Gαs/olf subunit containing G-proteins that dissociate to
Gβγ and Gαolf/s-GTP. Gαolf/s-GTP then stimulates the enzyme, adenylyl cyclase
12

(AC) which synthesizes and increases the concentration of cyclic AMP (cAMP).
In turn, cAMP activates protein kinase A (PKA) which will go on to phosphorylate
various targets (Kandel et al., 2012; Iversen et al., 2009).
In contrast, D2-like receptors inhibit AC through activation of Gαi/o subunit
containing G-proteins. Activation of D2-like receptors leads to inhibition of the
AC/cAMP/PKA signaling pathway. Activation of D2-like receptors also results in
Gβγ-mediated activation of PLC resulting in upregulated IP3 production.
Increases in IP3 generation gives rise to the release of ER Ca2+, and the
subsequent inactivation of L-type Ca2+ channels and Na+ channels (Kandel et al.,
2012; Iversen et al., 2009).
DRD1s and DRD2s can oligomerize to form heteroreceptors in certain
populations of cells. For example, D1/D2 heteromeric receptors have been found
in striatal neurons within the rat CNS (Hasbi et al., 2011). Ligand binding to
D1/D2 heteromers causes a Gαq-mediated increase in intracellular Ca2+ in a
PLC-dependent manner (Lee et al., 2004; Rashid et al., 2007).

1.6

Dopaminergic signaling in astrocytes
In this thesis, I focus on the putative interactions between

astrocytes and dopamine in vitro. This thesis employs immunocytochemical,
pharmacological, and molecular approaches to characterize the mechanisms by
which dopaminergic stimulation may influence hippocampal astrocytes in early
postnatal cultures.
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Cultured astrocytes respond with an increase in cAMP upon application of
dopamine, D1-like receptor agonist SKF38393, and apomorphine, a nonselective dopamine receptor agonist (Zanassi et al., 1999). These astrocytic
responses to dopamine are region-specific with the largest increase in cAMP
occurring in striatal astrocytes, followed by cortical and cerebellar Bergmann
astrocytes. Further, striatal astrocytes are found to express dopamine D1 and D2
receptor mRNA that is translate into DRD1 and DRD2 protein (Hansson et al.,
1988; Bal et al., 1994; Zanassi et al., 1999; Vrana et al., 1995). Gene and protein
expression studies demonstrate expression of dopamine receptors D1, D2, D3,
D4, and D5 in striatal and basal ganglia astrocytes (Hansson et al., 1988; Bal et
al., 1994; Zanassi et al., 1999; Miyazaki et al., 2004). These findings provide
important physiological implications in indicating that astrocytes can express
functional dopamine receptors which activate intracellular downstream cascades
similar to those in neurons.
Although expression of dopamine receptors in hippocampal astrocytes
has not been specifically studied, dopamine has been found to initiate large
intracellular calcium increases in cultured hippocampal astrocytes (Parpura and
Haydon, 2000). Another study performed in 2001 recognized a cortical
population of dopamine D2 receptor expressing astrocytes in monkey using
electron microscopy techniques (Khan et al., 2001). Further investigation by this
group revealed dopamine D2 receptor-mediated increases in calcium transients
in rat and mouse cortical astrocytes. A more recent study shows that knockout of
astrocytic dopamine D2 receptors in mice leads to disruption of αβ-crystallin
14

production resulting in systemic inflammation and marked astrocytic reactivity
(Shao et al., 2013).
Interestingly, some studies indicate that astrocytes can store and release
dopamine. Astrocytes have been shown to express dopamine transporters in
glioma cells (Russ et al., 1996), cultured cortical astrocytes (Inazu et al., 1999)
and in striatal tissue (Kittel-Schneider et al., 2012; Inazu et al., 2003). The
norepinephrine transporter has also been identified in cultured cortical
astrocytes, and may be responsible for dopamine uptake in these cells (Takeda
et al., 2002).
Overall, the literature is explicit in showing that astrocytic morphology may
change in response to environmental stimuli, that astrocytes can express
dopamine receptors, and that dopamine can induce changes in astrocytic
signaling in vitro. However, the consequences of chronically elevated dopamine
levels on astrocytes, as might be observed following exposure to drugs of abuse,
are not clear. I hypothesize that dopamine-induced morphological alterations in
cultured astrocytes are associated with astrocyte-bound dopamine receptormediated changes in molecular and functional phenotype. The findings of this
study are expected to have major implications for understanding astrocyte
function under conditions of elevated dopamine and for elucidating the
physiological role of dopamine-related activity in astrocytic cell populations within
the central nervous system

15

CHAPTER 2
METHODS

2.1

Primary rat hippocampal astroglial culture
Primary hippocampal astrocytes were taken from neonatal P1 - P2

Sprague-Dawley rat pups. The heads were removed and hippocampi were
dissected in petri dishes filled with ice-cold dissection medium comprising Hank’s
Balanced Salt Solution (HBSS; with Ca2+ or Mg2+ and phenol red; Sigma) and
HEPES (10mM; Sigma). The dissected hippocampi were then cut into pieces,
and dissociated by trypsin treatment (10µl/mL; Gibco), followed by trituration with
sterile glass pipettes. Cells were plated at various densities on 12mm glass
coverslips (low density) and 6-well plates (high density) pre-coated with poly-llysine (50µg/mL; Sigma). Cultures were maintained in DMEM/F12 (Gibco) media
supplemented with 10% fetal bovine serum (FBS), and stored in an incubator at
37ºC (5% O2/95% CO2). Cultured cell groups were subsequently selected and
treated with dopamine (75µM) or vehicle. Low density cultures were harvested
for immunocytochemical assays at DIV 10. Upon reaching 90% confluency (DIV
10-12), high density cultured astrocytes were harvested and used for qRT-PCR.
Where stated, pharmacological agents were added to culture media at listed
concentrations (See Table 2.1).
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2.2

Immunocytochemical assay
Astrocytes were plated on sterile glass 12mm coverslips in 35mm petri

dishes. After 10 DIV, the media was removed and the cells were washed twice in
1X PBS, pH 7.4. Cells were then briefly fixed in 4% paraformaldehyde (PFA),
and then washed again with 1X PBS three times. The cells were next treated
with .3% Triton-X (Sigma) for 15 minutes and washed once with 1X PBS.
Subsequent blocking of nonspecific sites was carried out in a 1X PBS solution
containing .1% tween 20 (Fisher) and 10% donkey or goat serum (Sigma) for 1 –
2 hours at room temperature. Coverslips were then incubated for 1 – 2 hours at
room temperature or overnight (ON) at 4° Celsius with primary antibodies against
GFAP, Olig1, CD11b, or NeuN (Refer to Table 2.2) before being washed in 1X
PBS three times. Fluorescent staining was then carried out by incubating
coverslips with secondary antibodies (1:1000; Life Technologies) conjugated to
fluorophore AlexaFluor 488 or 594 at room temperature in the absence of light for
1 hour. Once complete, cells were washed with 1X PBS three times before
application and incubation with DAPI (5ug/mL; Molecular Probes) for 10 minutes.
Coverslips were then rinsed once with ddH2O and mounted on glass slides with
Prolong Antifade mounting medium (Life Technologies). Cells were later
examined under a widefield fluorescent microscope using 10X, 20X, and 40X
objectives (Eclipse E200, Nikon). In all experiments, primary and secondary
antibody omission controls were used to confirm the specificity of
immunofluorescence labeling.
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2.3

Morphological analysis
For the purpose of determining the function(s) of exogenous dopamine in

the potential modulation of astrocyte morphology, the present study assessed
those alterations in GFAP using a measure of cell area and cell process count
using ImageJ software. For calculating GFAP-positive cell area, individual cells
were isolated in a 90240 pxl2 (figure 2.1a; area 1) selection box prior to
application of a color threshold to the cell. Cell area was then measured as pxl 2
(area 2), and % cell area occupied was calculated. For cell process count, only
primary processes extending directly from the cell body and at least 30 pixels in
length were counted (figure 2.1b).

2.4

Genetic characterization of primary cells
Reports have shown expression of dopamine receptor mRNA in cultured

astrocytes taken from striatum and basal ganglia (Hansson et al., 1988; Bal et
al., 1994; Zanassi et al., 1999; Miyazaki et al., 2004). Following dopamine
treatment, the expression of dopamine receptor (DRD1, DRD2, DRD3) mRNAs
was assessed by a quantitative real-time polymerase chain reaction (qRT-PCR)
method using specific primer sets for genes of DRD1, DRD2, and DRD3 (Table
2.3). Dopamine-induced changes in gene expression levels of GFAP and
ST8SiaI, a precursor of the cell surface ganglioside GT3 for which the A2B5
antibody binds to, will also be assessed. These results will provide support for
previous aims in confirming changes in protein and gene expression that
translate to phenotypical and functional alterations in astrocytes.
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A Quantitative RT-PCR method will be applied due to its precision and
sensitivity in determining even subtle changes in gene expression. All primary
cultures will be harvested after 10-12 days in culture. Total RNA was extracted
using TRIzol (Life Technologies) reagent and protocol along with an RNeasy Mini
Kit (Qiagen). Samples were homogenized and incubated in TRIzol (Life
Technologies) for 5 minutes before addition of chloroform and brief shaking.
Following a 3 minute incubation, samples were centrifuged at 4°C for 10 minutes
at maximum speed (≥10,000rpm). The aqueous phase was aspirated off and
transferred to a microcentrifuge tube before addition of 70% EtOH, centrifugation
at ≥10,000rpm for 15 seconds and collection of the precipitate from the RNeasy
mini column. This step was repeated adding 700µL Buffer RW1 and next 500µL
Buffer RPE to the mini column. Another 500µL of Buffer RPE was centrifuged for
2 minutes before the sample/mini column underwent another 2 minute “dry” spin
before being transferred to the final collection tube. Lastly, 15µL DEPC water to
elute the sample. RNA samples were quantified using NanoDrop
Spectrophotometer ND-2000 (Nanadrop Technologies) and checked for quality
and degradation via Bioanalyze.
RT-PCR (qPCR) was carried out to probe for expression of GFAP, DR1,
DR2, and DR3, ST8Sia I, RNan2 mRNA using the established protocol: DR1,
DR2, DR3, ST8siaI, Ran2, and GFAP mRNA transcripts were quantified using
oligonucleotide primers designed using the NCBI Primer-Designing tool and
subsequently analyzed via the BLAST database to ensure specificity of binding.
Primers were created and supplied by Eurofins Genomics (Table 2.3). GAPDH
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and HPRT were used as the housekeeping genes or internal standards. For each
primer being tested, 1000µL of primer mix was prepared: 200µL of 100µM
forward primer, 200µL of 100µM reverse primer, and 600uL of DEPC H2O.
Samples were diluted to 500ng/ µL with DEPC water before undergoing cDNA
synthesis. For each sample, 10µL of 2X SYBR Green Mix, 4µL of DEPC H2O,
and 1µl of cDNA sample was prepared and subsequently mixed with 5µL of
primer mix to a total volume of 20µl before pipetting into a 385-well plate. Realtime PCR was carried out using Bio-Rad CFX384 Real-Time PCR Detection
System. The following are the cycling parameters for all genes: initial
denaturation at 95ºC for 3 minutes, then 40 cycles of 95ºC for 20s and 60ºC for
20s. All transcripts were measured in each sample in triplicates. Expression
values were normalized to GAPDH and reported as a fold change
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a

b

Figure 2.1

Morphological analysis of GFAP stained cells

a) Example of GFAP-positive cell area measurements. Isolate cell using 90240pxl2 ROI,
eliminate noise and cell interference, color threshold the isolated cell and apply measure
function. b) Example of process length measurement.

Table 2.1

Summary of pharmacological agents used throughout thesis

Chemical

Chemical Abbreviation

Concentration

Duration

SCH

75μM
50µM

20min, 60min, 24Hr, 48Hr

SCH23390
Sulpiride

Sul

20µM

10 minutes

N-acetyl-L-cysteine

NAC

30 minutes

Sodium Metabisulfite

SMBS

5mM
50µM

Dopamine Hydrochloride DA HCL

Table 2.2

10 minutes

30 minutes

Summary of antibodies used for immunocytochemistry assay

Antibody

Source

Concentration

Duration

1° mouse anti-GFAP

Millipore

1:1000

2HR RT or 24HR 4°C

1° mouse anti-NeuN Millipore
2° donkey anti-mouse Life Technologies

1:500

2HR RT or 24HR 4°C

1:1000

1HR RT; in dark

1° rabbit anti-GFAP

Abcam

1:1000

2HR RT or 24HR 4°C

2° goat anti-rabbit

Life Technologies

1:1000

1HR RT; in dark

1° mouse anti-Olig1

R&D Systems

1:500

24HR 4°C

2° goat anti-mouse

Life Technologies

1:1000

1HR RT; in dark

1:100

24HR 4°C

1° mouse anti-CD11b Abcam
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Table 2.3

Summary of oligo primer sequences used for qRT-PCR

Gene

Sequence

R or L

DRD3

CTCCATCTCCAACCCTGATTT

L

DRD3

CAGCCTCAGACAGGAAGACTG

R

DRD2

L

DRD2

GCAATGCCCATGCTGTATAAC
GATGAAGGGCACGTAGAATGA

GFAP

ATCGTGGTAAAGACGGTGGAG

L

GFAP

ACTGGTGTGGATGGGAATTGG

R

NR1

CTTCACTCGTCTCTCTCAGCC

L

NR1

CACCACCTGTGTTGTTGTTGG

R

ST8SiaI

AAACCTGCTGTGGTCCAGAAA

L

ST8SiaI

GGCTGCACTCACCAAAAAGAG

R

Ran2

GTAACTCCCACAAAGGGTCCA

L

Ran2

GCTGTGTTGTATGTGCTGGTG

R

DRD1

GCGTGATCAGCGTGGACAGG

L

DRD1

AGGGCCATGTGGGCTTTGCC

R
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CHAPTER 3
RESULTS

To date, there have not been any published studies which report on the
morphological and/or phenotypical effects of dopamine in astrocytes. Yet, studies
highlight dopamine’s potential in inducing structural and phenotypical alterations
through astrocyte-bound dopamine receptors which may translate to changes in
astrocyte function. My results provide evidence that exogenous application of
dopamine can trigger morphological and phenotypic alterations in primary
cultured hippocampal astrocytes which may have implications for astrocytic
function.

3.1

Characterization of primary cultures
Before evaluating dopamine’s effects on astrocytes in culture, I first

verified the identity of cultured cell types. Thus, primary cultures were evaluated
for contaminating cell types via immunocytochemical assays using antibodies
against Olig1 (oligodendrocytes), CD11B (microglia), NeuN (neurons), and GFAP
(astrocytes), as well as a nuclear counterstain, DAPI (figure 3.1a-d). Among
DAPI-positive un-treated cells 22.6±0.01% stained for microglial marker, CD11b,
2±.007% of cells stained positive for NeuN, 86±0.02% were positive for GFAP,
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and 62±0.03% were positive for the oligodendrocyte marker, Olig1 (figure 3.1e;
at least 500 cells in each group analyzed from 3 different coverslips per group).
These findings indicate that some overlap between individual markers is possible
due either to non-specific staining or to co-expression within individual cells.
Nevertheless, the neuronal presence is negligible in these cultures and the
microglial presence is similar to that seen in previous studies (Saura, 2007).We
conclude that our culture conditions result in GFAP-positive, astroglia enriched
cell population. Future experimentation will incorporate techniques to further
enhance expression of astrocytes and reduce contamination with other cell
types.

3.2

Characterization of oligodendrocytes and astrocytes
We were interested in the high percentage of DAPI-positive cells

expressing Olig1 and investigated the possibility of overlapping Olig1 and GFAP
signals. Our findings demonstrated a high degree of GFAP & Olig1 coexpression (figure 3.2a-c). 26±0.05% of DAPI-positive cells were found to be
GFAP-negative/Olig1- positive, 17±0.05% were GFAP-positive/Olig1-negative,
and 56±0.07% were GFAP-positive/Olig1-positive (figure 3.2d; 418 cells
analyzed from 3 coverslips).
Expression of GFAP-positive progeny in oligodendroglial-speciﬁc promoter
lineage cells (OPCs) has been documented, and is a likely reason for the high
degree of GFAP/Olig1 co-expression observed in these cultures (Alghamdi et al.,
2015). A study carried out in the early 1980s identified an oligodendrocyte
precursor cell (O-2A) which, depending on the culture media conditions,
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developed into an oligodendrocyte or a process-bearing type II astrocyte (Raff et
al., 1983; Miller & Raff, 1984). Yet, subsequent studies indicated that these cells
may generate oligodendrocytes, type 1 astrocytes, or type 2 astrocytes in vitro
(Raff et al., 1983; Rao and Mayar–Proschel et al., 1997; Nishiyama et al., 2009).
Taken together, results support the concept that OPCs are polydendrocytes and,
given certain culture conditions, can differentiate into oligodendrocytes, type 1 or
type 2 astrocytes, and in some cases, neurons (Nishiyama et al., 2009; Najm et
al., 2012). The extent to which similar maturation trajectories exist in vivo is not
known.
My experiments highlight a close morphological association between
oligodendrocyte soma (Olig1) and astrocytes, where GFAP-positive astrocytic
processes completely encase oligodendrocytes. Other studies have also
observed this relationship, and suggest that oligodendrocytes may act as satellite
cells providing metabolic support for neurons and astrocytes (Rothstein and
Levison, 2005). Worth noting is that Olig1-positive cells and GFAP-positive cells
may form close morphological arrangements that are problematic to optimally
resolve using the immuno-fluorescent approach described above.

3.3

Morphometric analysis of dopamine treated astrocytes
To assess dopamine’s effects on astrocyte morphology, I examined the

expression of an astroglial marker, glial fibrillary acidic protein (GFAP) following
treatment with dopamine (75μM) for 1, 24 (not shown), and 48 hours.
Immunocytochemical staining with antibodies against GFAP and DAPI revealed
a pronounced and persistent dopamine-induced conversion from a non-stellated
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morphology to a stellated morphology (figure 3.3a-d). In fact, brief one hour
exposure to dopamine led to a significant 47±0.02% reduction in mean GFAPpositive cell area and produced an average of 4.5±0.44 more processes per
astrocyte (figure 3.3e,f). The significant structural changes observed after a 1
hour treatment endured for at least 48 hours, showing that cells attained an
average of 3.5±0.50 more processes per cell and a 15±0.025% reduction in
mean GFAP-positive cell area compared to the 48 hour control group maintained
in dopamine-free media (figure 3.3e,f).
Dopamine concentrations in the brain have been reported to be in low
nanomolar to low micromolar range (Smith et al., 1992; Zhang et al., 2009), lower
than the 75 M dopamine used in my studies. In preliminary dose-response
experiments, I incubated cultured cells with .1, 1, and 10µM dopamine for 1 hour.
My preliminary evidence indicates that a conversion from a non-stellated to a
stellated cell population can be seen at all three of these doses (figure 3.4a – c).
Incubation with 1 M resulted in 10% decrease of GFAP area and an average
increase of 1.6 processes relative to 0.1 M (figure 3.4d,e). Incubation with 10
M resulted in 15% decrease of GFAP area and an average increase of 2.6
processes per cell (figure 3.4d,e).These preliminary findings suggest that
dopamine effects may be observed at physiologically relevant concentrations.
Astrocytes are plastic cells and their structural, phenotypical, and
functional responses depend on their surroundings. Importantly, plastic changes
in astrocytes can promote plastic and physiological changes in the tripartite
synapse and surrounding neuronal networks. My results imply a role for
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astrocyte-bound dopamine-receptor mediated signaling cascades in inducing
plastic changes in astrocytes. Specifically, activation of dopamine D1-like
receptors leads to an increase of cAMP and increases in cAMP have been found
to significantly promote stellation of hippocampal and cortical astrocytes in
culture (Won and Oh, 2000). These observations indicate that hippocampal
astrocytes are sensitive to dopamine and may, through dopamine receptors, be
capable of mediating various responses within the CNS.

3.4

Phenotypical analysis of dopamine treated astrocytes
The morphogenic alterations brought about by dopamine exposure led me

to question whether these changes may translate to a shift in cells’ genetic
profile. Previous experiments have distinguished two distinct astrocytic
phenotypes in neonatal culture: A2B5-negative/Ran2-positive type 1 astrocytes
have fine processes and populate the gray matter while A2B5-positive/Ran2negative type 2 astrocytes have a clear stellate morphology and populate the
white matter (Raff et al., 1983; Oberheim et al., 2012). Additionally, dopamine’s
swift (1 hour) and dramatic effects on astrocyte structure implied a potentially
rapid shift in astrocyte phenotype; thus, a 20 minute incubation was employed
because mRNA changes precede protein changes.
Following incubation with dopamine (75µM) for 20 and 60 minutes, cells
were harvested for RNA extraction. The expression of Ran2 and ST8Sia1, a
precursor of the cell surface ganglioside GT3 that binds A2B5 and a marker of
type 2 astrocytes, mRNAs were analyzed by qRT-PCR method using specific
primer sets for A2B5 and ST8Sia1 (See table 2.3). Dopamine exposure was
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found to significantly downregulate expression of Ran2 and upregulate ST8Sia1
mRNA (figure 3.4). These findings parallel the morphological change from a type
1-like astrocyte with many fine processes to a type-2 like stellated astrocyte
witnessed following dopamine treatment and may represent a dopamine-induced
shift from a type 1 astrocyte to a type 2 astrocyte in culture.

3.5

Molecular analysis of dopamine receptor mRNA
Reports have shown expression of dopamine receptor mRNA in cultured

striatal and basal ganglia astrocytes (Hansson et al., 1988; Bal et al., 1994;
Zanassi et al., 1999; Miyazaki et al., 2004).The morphogenic changes brought
about by dopamine exposure led me to question whether hippocampus-derived
astrocytes express dopamine receptors. Furthermore, does dopamine receptormediated signal transduction occur in astrocytes? In this thesis, I examined the
expression of dopamine receptor mRNA in primary cultured astrocytes from rat
hippocampus. Following incubation with dopamine (75µM) for 20 and 60 minutes,
cells were harvested for RNA extraction. The expression of dopamine receptor
D1, D2, and D3 mRNAs was analyzed by qRT-PCR method using specific primer
sets for dopamine receptors mentioned (see table 2.3). Dopamine exposure was
found to upregulate expression of all dopamine receptors screened (D1, D2, and
D3); however, dopamine receptor D1 mRNA had the strongest level of
upregulation with approximately a 2–fold increase after 20 minutes and 60
minutes of dopamine exposure (see figure 3.4). Results confirm expression of
dopamine receptor mRNA in cultured hippocampal astrocytes and may indicate a
dopamine receptor presence on astrocytes. Finally, these observation hold
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potential as a marker of dopamine receptor-mediated signal transduction in
astrocytes.

3.6

Morphogenic effects of dopamine in presence of antioxidants
Dopamine can undergo oxidation in cell culture media and oxidative

processes have been shown to drive changes in astrocyte morphology (Clement
et al., 2002; Pekny and Nilsson, 2005; Sofroniew, 2009; Vaarmann et al., 2010).
Sodium metabisulfite (SMBS) and N-acetyl-L-cysteine (NAC) are commonly used
to prevent the oxidation of catecholamines. Thus, to examine the role of oxidative
processes in dopamine-induced astrocyte stellation, I first applied NAC (5mM) to
cultured cells 30 minutes prior to 1 hour dopamine exposure. Following 1 hour
treatment with dopamine, cells were fixed and processed for antibodies against
GFAP and DAPI. Subsequent analysis determined those alterations in GFAP
using a measure of cell area and cell process count as described before. This
treatment did not lead to a significant difference in GFAP-positive cell area or
process number between the NAC pre-application group and dopamine
treatment alone (figure 3.7a,c,d). Another group of cells was pre-incubated with a
different antioxidant, SMBS (50µM), 30 minutes prior to exposure to dopamine
for 1 hour. Again, there was no significant difference in GFAP-positive cell area
or process number compared to cells treated with dopamine alone (figure
3.7b,c,d).
ROS-induced reactivity in astrocytes leads to changes in the morphology
of astrocytes including cell hypertrophy, swelling, and thickening of processes
(Vaarmann et al., 2010). Upregulated fluorescent intensity of GFAP signal is a
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common marker of astrocyte reactivity; however, I observed no significant
difference in intensity of GFAP expression (figure 3.6). Therefore, the dopamineinduced morphological changes seen in my experiments do not reflect astrocytic
reactivity as measured by intensity of GFAP signal. Individual processes are
thicker following dopamine, but it is unclear if this represents swelling of the
existing processes or collapse of multiple fine processes (figure 3.3). Treatment
with NAC at similar concentrations effectively blocks LPS and cocaine-induced
astrocyte reactivity (Paintlia et al., 2008; Badisa et al., 2015) whereas dopamineinduced stellation persists in the presence of SMBS and NAC (figure 3.7). This
argues against dopamine-induced reactivity in our cultures. Furthermore, while
concentrations of 75 µM are considered well above physiological range, these
high concentrations have not been found to induce pathological responses, but
instead are thought to be a major reaction to dopamine (Vaarmann et al., 2010).
Therefore, immune-like response to ROS exposure is unlikely to account for DAinduced changes in astrocyte morphology.

3.7

Morphogenic effects of dopamine in presence of DR antagonists
Are these morphogenic and genomic effects mediated by dopamine

receptors? We initially examined the effects of exogenous dopamine in the
presence of the D1-like receptor antagonist, SCH23390 (20µM). Cells were pretreated with SCH23390 for 30 minutes prior to dopamine application. Following 1
hour treatment with dopamine, cells were fixed and processed for antibodies
against GFAP and DAPI (figure 3.8a,b). Subsequent analysis determined those
alterations in GFAP using a measure of cell area and cell process count as
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described before. Results indicated that SCH23390 pre-treatment effectively
blunted dopamine’s morphogenic effects, as evidenced by only slight increase in
average process number and no significant difference in cell body area when
compared to dopamine treatment alone (figure 3.8c, d). Pre-treatment with D2like receptor antagonist, sulpiride, demonstrates similar results to those of the
SCH23390 treated group. The presence of sulpiride lead to an increase from 1.5
processes per cell in control conditions to 4 processes (an average gain of 2.5
processes) per cell in D2-like receptor antagonist conditions (figure 3.8d).
Additionally, no significant changes in GFAP-positive cell body area were
observed (figure 3.8c).
Application of SCH23390 (20μM) or Sulpiride (50μM) prior to treatment
with dopamine (75μM) blunts dopamine’s morphogenic effects (figure 3.8a -d).
These findings indicate that dopamine’s effects are mediated through astrocytebound dopamine receptors and their downstream pathways. It is possible that a
synergistic interaction between D1-like and D2-like receptors is present since
antagonists at these receptors applied individually did not completely block
morphogenic effects of dopamine. Alternatively, unidentified dopamine receptorindependent intracellular pathways may contribute to dopamine-induced
stellation. It is also interesting to note that attenuated stellation following D1-like
receptor antagonist application is in line with findings of stellation induced by
stimulation of cAMP signaling (Won and Oh, 2000). This would suggest that
other receptors positively coupled to cAMP activity (e.g. certain β-adrenergic,
muscarinic, and serotonin receptors) may also trigger morphogenic changes
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similar to dopamine. However, attenuated stellation following D2-like receptor
antagonist application implies involvement of other intracellular signaling
cascades. Future experiments will investigate these possibilities.
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Figure 3.1

Oligo

Immunocytochemical staining with GFAP (a), cd11b (b, microglia),
NeuN (c, neurons), and Olig1 (d, oligodendrocytes) in un-treated cell populations
allowed for quantification of distinct cell types. Graph (e) indicates that cultures
consisted of approximately 23% microglia, 2% neurons, 86% astrocytes, and
62% oligodendrocytes. Scale bar, 75µm.
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Figure 3.2

GFAP & Oligo1

Immunocytochemistry using antibodies against DAPI (c, blue),
Olig1 (b, red), and GFAP (a, green) demonstrates a high degree of GFAP &
Olig1 co-expression (d, e). Scale bar, 75µm.
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Figure 3.3

Morphometric analysis of primary astrocytes.
Immunocytochemical staining of astrocytes treated with vehicle and
dopamine for durations of 1 and 48 hours (a – d). Images illustrate staining
of GFAP (red) and DAPI (blue). Scalebar, 75µM. Graphs (e) and (f)
illustrate the change in GFAP(+) cell surface area and process number in
dopamine-treated cells compared to control. (e) Values represent average
percent GFAP(+) area occupied. (f) Values represent the average number
of primary processes per cell. For graphs: **, p< .005 relative to control,
paired t-test; n= 35-50 cells.
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10µM

Morphometric analysis of rat primary astrocytes following 1 hour
incubation with DA at .1, 1, and 10µM (a – c). Images illustrate staining of GFAP
(green) and DAPI (blue). Scalebar, 75µM. The graphs (d) and (e) illustrate the
change in GFAP (+) cell surface area and process number.
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fluorescence intensity
GFAP
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Fluorescence
GFAP

Cultured cells were treated with dopamine hydrochloride (75µM)
for 20 and 60 minutes before being harvested for RNA extraction. Quantitative
RT-PCR was used to examine changes in astrocytic mRNA expression profile. *
p< .05, ** p<.01, one-way ANOVA, Tukey’s post-hoc vs. 0 min. #, p<0.05, ##,
p<0.01, one-way ANOVA, Tukey’s post-hoc vs. 20 min.
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Figure 3.6

GFAP Fluorescence Intensity. Following treatment with dopamine
for 1 hour, cultured cells were taken and stained with an antibody against GFAP.
A measure of GFAP signal intensity was taken between control and treatment
groups. The graph illustrates no change in GFAP fluorescent signal intensity
following treatment with dopamine (75µM) relative to control cells, student t-test;
n = 35
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SMBS

Images depict GFAP (green) and DAPI (blue) in primary cultured
astroglia. Scalebar, 75µm. Antioxidants, N-acetyl-l-cysteine (a) and sodium
metabisulfite (b) do not blunt dopamine’s morphological effects. The graph (c)
and (d) illustrate the change in cell surface and process number in dopaminetreated cells pre-incubated with N-acetyl-l-cysteine (B) Values expressed
represent average percent GFAP positive area occupied. (C) Values represent
the average number of primary processes per cell within each treatment group.
For graphs: antioxidant treatments were not significant relative to dopamine
treatment, student t-test; n= 35-50 cells.
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DR2 antag

Images depict GFAP (green) and DAPI (blue) stain in primary
cultured astroglia. Scalebar, 75µM. D1 (a) and D2-like (b) receptor antagonists
blunt dopamine’s morphological effects. The graphs (c) and (d) illustrate the
change in cell surface and process number in dopamine-treated cells preincubated with dopamine receptor antagonists (B) Values expressed represent
average percent GFAP positive area occupied. (C) Values represent the average
number of primary processes per cell within each treatment group. For graphs:
**, p< .0001 relative to dopamine treatment, one-way ANOVA, Bonferroni’s post
hoc vs. DA; n= 35-50 cells.
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CHAPTER 4
DISCUSSION

4.1

Dopamine triggers a shift in astrocyte morphology
To morphologically assess astrocytes’ (re)organization of intermediate

filaments following treatment with dopamine, I examined the expression of an
astroglial marker, GFAP. The initial observation made in this thesis is that
dopamine can trigger a significant change in astrocyte morphology characterized
by a shift from a polygonal form to a stellate form accompanied by a reduction in
overall GFAP-positive area. As this has not been demonstrated in culture
literature, this is the first report of a dopamine-induced morphological change in
astrocytic morphology.
Dopamine is a neurotransmitter, which not only can regulate behavior,
movement, endocrine, cardiovascular, renal, and gastrointestinal functions, but
also serves as an essential molecule bridging the nervous and immune systems
(Yan et al., 2015; Beck et al., 2004). Prior studies have shown that dopamine,
DRD1, and DRD2 signaling exert anti-inflammatory action on both the CNS and
peripheral organs (Shao et al., 2013; Yan et al., 2015). Dopamine has been
found to inhibit LPS-induced inflammatory effects in different cell types such a
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macrophages, lymphocytes, and neurons (Yan et al., 2015; Beck et al., 2004).
Findings of functional relevance show that astrocytic dopamine D2 receptor
(DRD2)-deficient mice present significant inflammatory response(s) in the CNS
and D1 receptor (DRD1) signaling prevents LPS-induced systemic inflammation;
together, these findings imply a role of dopamine and its downstream pathways
in mediating anti-inflammatory responses (Shao et al., 2013; Yan et al., 2015).
Yet, it is important to note that while lower concentrations work to protect and
prevent cell death (possibly through action on DRD1s), higher concentrations of
dopamine serve to promote apoptosis in CNS and PNS cell systems (Shao et al.,
2013; Beck et al., 2004). This pro-apoptotic action of high dopamine
concentrations may link closely to those inflammatory responses seen in
microglia and astrocytes following habitual substance use.
Review of the literature supports that activation of astrocytes can be
triggered by various factors. LPS has been consistently used to induce activation
of astrocytes in culture; however, little is known of the potential of dopamine to
alter the state of individual astrocytes or the astrocytic network as a whole.
Reports suggest that astrocytic dopamine-dependent signaling may be regulated
by the breakdown of dopamine via monoamine oxidase to produce reactive
oxygen species (ROS; Vaarmann et al., 2010). Importantly, ROS has been
implicated in a ubiquitous phenomenon referred to as reactive astrogliosis
(Sofroniew, 2009). Over the years, the reactive astrocyte has collected numerous
definitions concerning its morphology, molecular prompts, and functional
ramifications; however, due largely to astrocytes’ complexity and heterogeneity,
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the definition of reactive astrogliosis remains ambiguous (Sofroniew, 2009;
Vaarmann et al., 2010; Renner et al., 2013). Moreover, the definition of reactivity
in astrocytes is likely to operate on a spectrum, rather than an all or none
response (Sofroniew, 2009). To assess the potential of ROS in promoting
stellation and morphological changes in cultured astrocytes, two different
antioxidants, N-acetyl-L-cysteine and sodium metabisulfite, were applied prior to
dopamine exposure. Application of these antioxidants did not significantly
prevent dopamine-induced morphogenic changes (i.e., GFAP+ cell area
reduction, stellation). Therefore, immune-like response to ROS exposure is
unlikely to account for DA-induced changes in astrocyte morphology.
The concentration of dopamine used in this study (75µM) is above the
physiological range of tonic brain dopamine measured by microdialysis (Goto
and Grace, 2005), but within range of dopamine concentrations applied to brain
slices and cultured cells in a number of previous studies (Parpura and Haydon,
2000; Khan et al., 2001; Liu et al., 2009; Vaarmann et al., 2010; Requardt et al.,
2010). These ‘maximal’ concentrations have not been found to exert pathological
effects, but instead are regarded as dramatic response(s) to dopaminergic
stimulation (Vaarmann et al., 2010). Moreover, my preliminary studies indicate
that lower concentrations of dopamine (0.1, 1, and 10 M) can trigger stellation
similar to that observed at higher (75 M) concentration. A quantitative analysis
of these morphological changes is currently under way.
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4.2

Dopamine triggers changes in astrocyte’s molecular profile
The findings of the current study reveal that astrocytes are sensitive to

dopamine, and that brief exposure to dopamine causes a striking change (nonstellated to stellated) in cultured hippocampal astrocyte morphology.
Previous experiments have distinguished two types of astrocytes in
primary culture as determined on the basis of morphology, as well as the binding
of GFAP and A2B5 antibodies (Raff et al., 1983). Following stimulation with
dopamine, ST8SiI, a precursor of the cell surface ganglioside GT3 for which
A2B5 binds and a genetic marker of type 2 astrocytes, was found to be
significantly upregulated. Providing support for a dopamine-induced phenotypic
shift from a type 1 to type 2 astrocyte, Ran2, a genetic marker of type 1
astrocytes was significantly decreased following exposure to dopamine. These
results imply a significant role for dopamine in inducing plastic and phenotypical
alterations through an astrocyte-bound dopamine receptor which may translate to
changes in astrocytic function, as well as astrocytic effects on synaptic
transmission.
An additional finding in this project is that dopamine can promote
upregulation of dopamine receptor DRD1, DRD2, and DRD3 mRNA in cultured
hippocampal astrocytes. In fact, exposure to dopamine for 20 minutes resulted in
a highly significant increase in DRD1 mRNA. Increases in cAMP have been
found to significantly promote stellation of hippocampal and cortical astrocytes in
culture (Won and Oh, 2000). Therefore, D1-like receptor stimulation may be a
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key ingredient in this morphological and molecular transformation as dopamine
D1 receptor activation leads to stimulation of adenylyl cyclase, and subsequent
increases in cyclic AMP (cAMP). However, in the present study, incubation with
dopamine receptor D2 antagonist, sulpiride, also prevented stellation. The
actions of DA are mediated by different G-protein coupled receptors which are
divided into two major families based on their ability to stimulate (D1-like) or
inhibit adenylate cyclase (D2-like; Beaulieu et al., 2011). However, D1 and D2
dopamine receptors can also form functional heterooligomers in astrocytes, and
signal preferentially through the Gq-PLC pathway (Beaulieu et al., 2011).
It is of note that expression of dopamine receptor mRNA has been
observed in cultured astrocytes of striatum and basal ganglia; however, their
expression in hippocampal astrocytes has not been previously reported
(Hansson et al., 1988; Bal et al., 1994; Zanassi et al., 1999; Miyazaki et al.,
2004). These findings indicate that hippocampal astrocytes are sensitive to
dopaminergic activity and express dopamine receptors that may be capable of
mediating various responses and functions within the CNS (Shao et al., 2013;
Miyazaki et al., 2004; Beck et al., 2004; Zhang and Barres, 2010).

4.3

Dopamine exerts its effects via dopamine receptors
The third major finding provides evidence for dopamine receptor mediated

changes in cultured astrocytes exposed to dopamine. The morphogenic effects
of dopamine were significantly blunted in cultured astrocytes pre-treated with
dopamine D1-like receptor antagonist, sulpiride and D2-like receptor antagonist,
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SCH23390. Both antagonists were effective in blocking dopamine’s ability to
promote stellation and changes in GFAP-positive area in cultured astrocytes.
Pre-treatment with D1 and D2-like antagonists reveal a 10% maximal reduction
in GFAP-positive cell body coverage (compared to control), and a maximal
average gain of 2.5 more processes per cell (compared to 6 processes in cells
treated with dopamine alone). I believe my evidence supports a potential role for
D1-like receptors and D2-like receptors in regulating dopamine-induced changes
in astrocytic morphology and molecular profile. Literature provides support for
this theory in demonstrating that signaling effects of dopamine on calcium activity
in astrocytes are largely mediated by D1 and D2-like receptors (Liu et al., 2009).
Supporting this hypothesis is the finding that stimulation of cAMP signaling can
also lead to astrocyte stellation (Won and Oh, 2000).
While the present study does imply a role of astrocyte-bound D1-like and
D2-like receptor action in the presence of dopamine, my findings do not produce
evidence telling of potential expression of an astrocyte-bound D1/D2 heteromer
on astrocytes. Dopamine D1 and D2 receptors have been proposed to form
hetero-oligomers that couple to Gαq proteins, and SKF83959 has been proposed
to act as a biased agonist that selectively activates these receptor complexes to
activate Gαq and thus phospholipase C (PLC; Frederick et al., 2015; Hasbi et al.,
2011). Further, D1/D2 heteromers are thought to be implicated in the
pathophysiology of schizophrenia, depression, and addiction (Frederick et al.,
2015; Hasbi et al., 2011). Future experiments investigating the potential of an
astrocyte-bound D1/D2 heteromer in mediating the changes witnessed in this
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study could reveal a novel signaling pathway by which astrocytes regulate the
brain’s environment.
Awareness of the distinct signaling pathways coupled to these receptors,
as well as their potential downstream targets is essential to understanding the
potential effects of dopamine on astrocytes. While the downstream signaling
pathways of D1 and D2-like receptors are well understood, it must be noted that
nearly all investigation has been directed towards the dopaminergic signaling
mechanisms taking place in and among neurons. Thus, the presumable concept
of dopamine induced astroglial intracellular signaling cascades may diverge in
certain manners.

4.4

Caveats of investigating dopaminergic reactions in vitro
While this study allows for establishment and understanding of a basic

mechanistic model of dopamine’s effects on astrocytes, it does not directly reflect
physiological conditions. Thus, I plan to relate these findings to structural and
functional plasticity of mature astrocytes in brain slices.
An additional issue facing this in vitro study is the manner of dopaminergic
stimulation. Exogenous application of dopamine (or dopamine agonists) is the
most traditional way of activating cells in vitro; however, in vivo dopaminergic
innervation of forebrain regions is limited. Further, hippocampal dopamine is
taken up by norepinephrine transporters (NETs) found on noradrenergic axon
terminals (Carboni et al., 1990; Borgkvist et al., 2012) and astrocytes (Takeda et
al., 2002). Therefore, the amount of dopamine applied in culture may degrade at
a slower rate than in slice preparations. Further experimentation is needed in
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order to more closely relate these findings to structural and functional plasticity of
astrocytes in vivo. Thus, in establishing an in vivo or in situ model, the caveat(s)
of replicating physiological mechanisms will need to be considered.

4.5

Astrocytes and dopamine: future directions
As this is the first report of morphogenic effects of dopamine on cultured

astrocytes, and a single concentration (75µM) was tested, future experimentation
will extend our preliminary dose-response findings. Thus, in applying dopamine
HCL at concentrations of .1, 1, and 10µM, I can clarify the relationship between
dose and occurrence of morphogenic and molecular effects in cultured
astrocytes.
Dopamine may exert its effects on astrocytes that are not solely mediated
by dopamine receptors. These alternative signaling pathways could reveal
themselves to be more effective in dopaminergic regulation of astrocyte activity,
and thus potentially contribute to changes in neuronal interactions. Traditionally,
dopamine receptors are classified based on their control of the cAMP signaling
cascade. In fact, dopamine receptors can regulate this pathway in astrocytes
(Won and Oh, 2000; Zanassi et al., 1999; Li et al., 2006). Future investigations
will provide more detail as to the role of cAMP-mediated pathways by use of
analogous activators, such as 8-CPT-cAMP, and inhibitors, such as cAMP-Rp, of
this pathway (Won and Oh, 2000). Additionally, alternate downstream signaling
pathways, such as those associated with D2-like receptors, or D1/D2 heteromers
will be considered for their potential in contributing to the observed alterations.

47

While morphogenic analysis following pre-treatment with dopamine
receptor antagonists has been carried out, molecular investigation using a qRTPCR method has not been carried out. Therefore, future directions will include
treatment of primary cultured cells with D1-like and D2-like receptor antagonists
followed by genomic analysis using qRT-PCR. I expect that the presence of
dopamine receptor antagonists will blunt dopamine’s ability to upregulate
ST8Sia1 mRNA, as well as block upregulation of dopamine receptor D1, D2, and
D3 mRNAs. These qRT-PCR experiments will be supplemented with
immunocytochemical analyses of D1, D2, and D3 receptor expression.
Additionally, RNA-sequencing will be used to screen the entire astrocyte
transcriptome in order to identify dopamine-induced alterations at the wholegenome level.

4.6

Conclusion
This thesis provides evidence of astrocytic alterations in response to

dopamine. It illustrates a dopamine receptor-mediated change in astrocyte
morphology and molecular makeup in vitro, and provides a framework for which
future investigative models can be built from. My findings that dopamine
receptors on cultured hippocampal astrocytes enable structural and phenotypical
plasticity imply that astrocytic dopaminergic signaling may influence not only
astrocytic function, but may also be involved in synaptic activity and plasticity.
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